These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33358430)

  • 1. Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
    Lønning PE
    Trends Cancer; 2021 Mar; 7(3):181-185. PubMed ID: 33358430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug combinations: dangerous liaisons or great expectations?
    Ratain MJ
    Ann Oncol; 1999 Apr; 10(4):375-6. PubMed ID: 10370777
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical trials. Experimental cancer therapies move to the front line.
    Couzin-Frankel J
    Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
    [No Abstract]   [Full Text] [Related]  

  • 4. Novel agents and future directions for refractory breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers.
    Agarwal R; Cangemi NA; Epstein AS; Harding J; Reidy-Lagunes D; Saltz LB
    J Natl Cancer Inst; 2020 May; 112(5):438-442. PubMed ID: 31834379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric drug-trial recruitment: an institutional review board perspective.
    Rakowsky A
    Pediatrics; 2011 Nov; 128(5):e1319-20; author reply e1320. PubMed ID: 22045804
    [No Abstract]   [Full Text] [Related]  

  • 7. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
    Watanabe T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should participation in vaccine clinical trials be mandated?
    Sheehy S; Meyer J
    Virtual Mentor; 2012 Jan; 14(1):35-8. PubMed ID: 23116915
    [No Abstract]   [Full Text] [Related]  

  • 10. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other options in the treatment of advanced breast cancer.
    Cobleigh MA
    Semin Oncol; 2011 Jun; 38 Suppl 2():S11-6. PubMed ID: 21600380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating novel treatment strategies into conventional therapy.
    Estey EH
    Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
    [No Abstract]   [Full Text] [Related]  

  • 13. Waldenström macroglobulinemia: is newer really better?
    Gertz MA
    Leuk Lymphoma; 2010 Dec; 51(12):2152-3. PubMed ID: 21067441
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained disease control in transplant-ineligible patients: the role of continuous therapy.
    Palumbo A; Niesvizky R
    Leuk Res; 2012 Nov; 36 Suppl 1():S19-26. PubMed ID: 23176720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
    [No Abstract]   [Full Text] [Related]  

  • 16. SOP 03: Preparation and structure of trial protocols.
    Onkologie; 2003 Oct; 26 Suppl 6():11-4. PubMed ID: 23570179
    [No Abstract]   [Full Text] [Related]  

  • 17. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 18. Trial watch: Lung cancer trial aims to bolster personalized medicine.
    Harrison C
    Nat Rev Drug Discov; 2014 Jun; 13(6):407. PubMed ID: 24875087
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do research ethics committees say about applications to do cancer trials?
    Dixon-Woods M; Angell E; Tarrant C; Thomas A
    Lancet Oncol; 2008 Aug; 9(8):700-1. PubMed ID: 18672207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.